SLNO - カプニア （Soleno Therapeutics Inc.）

REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.

Soleno Therapeutics press release (SLNO): Q4 GAAP EPS of -$0.58 beats by $0.22.As of December 31, 2022, Soleno had cash and cash equivalents of approximately $14.6 million.

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022.

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time.

While everyone knows that in order to have a market, there must be bulls and bears, that’s not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position. At some point, though, those borrowed shares must be returned. For the bears, they can be returned either at a profit or a loss. Now, in order to panic the bears into buying back their borrowed shares before they rise too much, contrarian bulls can deliberately bid up negatively targeted securities. Therefore, the top short-squeeze candidates offer an incredibly lucrative opportunity to make big money quickly. Still, it’s important to remember the cardinal rule about this contrarian practice: flawed companies usually attract heavy short interest. As a bull, even if you make money on your trade, you probably don’t want to hang around too long. Otherwise, your fellow bulls might dump shares on you.

Clinical-stage biotech Soleno Therapeutics, Inc. (SLNO) dropped ~13% in the pre-market trading Friday as the company shares began trading on a split-adjusted basis following a…

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Eye-popping stocks: Soleno Therapeutics, Inc. (NASDAQ:SLNO 0.25%), Borqs Technologies, Inc. (NASDAQ:BRQS 1.68%) appeared first on Stocks Equity .

Soleno Therapeutics Inc. (NASDAQ:SLNO) concluded the trading at $0.19 on Thursday, August 11 with a rise of 9.55% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $0.18 and 5Y monthly beta was reading 0.28 with its price kept floating in the … Analysts Release Price Targets And Ratings For Soleno Therapeutics Inc. (SLNO) Read More »

REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2022.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enthralling stocks: First Wave BioPharma, Inc. (NASDAQ:FWBI -0.32%), Soleno Therapeutics, Inc. (NASDAQ:SLNO 3.27%) appeared first on Stocks Equity .

Soleno Therapeutics Inc. (NASDAQ:SLNO)’s traded shares stood at 0.82 million during the last session, with the company’s beta value hitting 0.29. At the close of trading, the stock’s price was $0.17, to imply a decrease of -5.00% or -$0.01 in intraday trading. The SLNO share’s 52-week high remains $1.04, putting it -511.76% down since that … Soleno Therapeutics Inc. (NASDAQ: SLNO) Surged -46.71% In 6 Months – Here’s What Happens Next Read More »

Soleno Therapeutics Inc. (NASDAQ:SLNO) price closed lower on Monday, July 25, dropping -1.26% below its previous close. A look at the daily price movement shows that the last close reads $0.17, with intraday deals fluctuated between $0.1717 and $0.18. The company’s 5Y monthly beta was ticking 0.38. Taking into account the 52-week price action we … Soleno Therapeutics Inc. (NASDAQ: SLNO) Could Pass $7.00 In One Year Stock Forecast Read More »

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Deliciously stocks You Should follow: Soleno Therapeutics, Inc. (NASDAQ:SLNO -6.72%), DURECT Corporation (NASDAQ:DRRX -3.49%) appeared first on Stocks Equity .

Soleno Therapeutics Inc (NASDAQ: SLNO ) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for Prader-Willi syndrome (PWS). The FDA acknowledged that data from a proposed randomized withdrawal phase of Study C602 would have the potential to address its … Full story available on Benzinga.com

Shares of small-cap penny stock Soleno Therapeutics, Inc. (NASDAQ: SLNO ) shares are trading higher after the company provided a regulatory update following recent communications with the FDA regarding the development of DCCR for the treatment of Prader-Willi syndrome. Earlier this year, Soleno submitted a proposal to add a randomized withdrawal period to Study C602 in order to obtain additional controlled data … Full story available on Benzinga.com